Artelo Biosciences, INC 10-Q quarterly reports

Artelo Biosciences filed its Q2 2026 Form 10-Q, detailing ongoing R&D efforts and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Artelo Biosciences reported increased net losses and a going concern warning for Q3 2025, despite positive interim clinical trial results for ART27.13 and ART26.12, and successful capital raises.

Artelo Biosciences reported a widened net loss in Q2 2025, alongside significant capital raises and a new strategy to invest heavily in Solana (SOL) cryptocurrency.

Artelo Biosciences announces its Q1 2025 results, highlighting clinical trial progress alongside concerns about its ability to continue as a going concern due to ongoing losses and the need for additional funding.

Artelo Biosciences reports a net loss of $1.132 million for the three months ended September 30, 2024, and provides an update on its clinical programs and financial position.

Artelo Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $4.9 million for the six months ended June 30, 2024, while advancing its clinical programs.

Artelo Biosciences reported a net loss of $2.483 million for the first quarter of 2024, while highlighting advancements in their clinical programs.